Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies

Abstract Chimeric antigen receptor (CAR)-engineered T cell therapy holds promise for treating myeloid malignancies, but challenges remain in bone marrow (BM) infiltration and targeting BM-resident malignant cells. Current autologous CAR-T therapies also face manufacturing and patient selection issue...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yan-Ruide Li, Ying Fang, Siyue Niu, Yichen Zhu, Yuning Chen, Zibai Lyu, Enbo Zhu, Yanxin Tian, Jie Huang, Valerie Rezek, Scott Kitchen, Tzung Hsiai, Jin J. Zhou, Pin Wang, Wanxing Chai-Ho, Sunmin Park, Christopher S. Seet, Caspian Oliai, Lili Yang
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-02-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-025-56270-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!